Related Experiment Video
Updated: Jan 16, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Dissociation Between Tumor Response and PTTM Progression During Entrectinib Therapy in NTRK Fusion-Positive Colon
Hideki Nagano1, Shigekazu Ohyama1, Atsushi Sato1
1Department of Surgery, Marunouchi Hospital, Matsumoto 390-8601, Nagano, Japan.
A rare case of pulmonary tumor thrombotic microangiopathy (PTTM) occurred in colon cancer treated with entrectinib. Despite tumor response, PTTM progressed, leading to fatal respiratory failure, highlighting the need for vascular-targeted therapies.
Area of Science:
- Oncology
- Pathology
- Pharmacology
Background:
- Pulmonary tumor thrombotic microangiopathy (PTTM) is a rare vascular complication.
- Neurotrophic tropomyosin receptor kinase (NTRK) fusion-positive cancers can be treated with TRK inhibitors like entrectinib.
More Related Videos
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
08:12Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019